Champion Exceptional Entrepreneurs
in Healthcare and Life Science.

ProfoundBio, founded in 2018, operating in both Seattle, US, and Suzhou, China，is a biotech company developing antibody-drug conjugates (ADCs) and other antibody-based therapeutics with the potential to cure cancer. Based on its innovative drug-linker technology, it has developed a next-gen ADC platform with better tissue penetration and wider therapeutic windows. The company's pipeline focuses on treating solid tumors with multiple programs in clinical development.

The founding team of ProfoundBio are all ADC industry veterans with decades of research and development experience handling this powerful class of drugs.

K2 Venture Partners led Series Pre-A investment in 2020, also the company's first institutional financing.

ProfoundBio was acquired by Genmab for USD 1.8 Bn in cash in 2024.

LTZ therapeutics is an immunotherapy-focused biotech company pursuing the development of novel therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need, founded in Shenzhen, China in 2021. LTZ therapeutics is dedicated to developing immunotherapies capable of overcoming resistance and boosting anti-tumor immunity based on reverse translational science and emerging biology of tumor microenvironment -- breaking new ground in the biotech industry in both China and worldwide.

The founding team and the scientific advisory committee have profound accumulation and successful experience in various aspects of immunooncology, tumor microenvironment regulation, protein drug design and clinical translation.

K2 Venture Partners led the Pre-A round of financing in 2021 and was deeply involved in the company establishment.

SanegeneBio is a global RNAi innovator founded in Suzhou, China and Boston, US in 2021. The company has established its own RNAi platform based on its proprieatory technology in nucleic acid modification and drug delivery. The platform has been validated with enhanced gene silencing with great safety profiles across different tissues. It will be applied to treat both common and rare diseases in metabolism, oncology, immunology, ophthalmology, as well as central nervous system.

The founding team consists of pioneering scientists with decades of industry experience in the RNAi field. The team has profound and comprehensive experience in research and development.

K2 Venture Partners invested in SanegeneBio as the sole investor in early 2021 in its angel round, and was greatly involved in the company launch. It has also continued supporting the company in its subsequent rounds.

Founded in Shanghai, 2021, YolTech Therapeutics is committed to the development of a new generation of in vivo gene editing combining mRNA delivery and gene editing. The company has built a strong pipeline targeting genetic diseases and cardiometabolic diseases, through the continuous optimization of editing tools including CRISPR, base editing and other next-generation editors, together with its innovative improvement on mRNA and LNP delivery.

The core team includes well-known scientists in the field of gene editing, Dr. Yuxuan Wu, a principal investigator at the School of Life Sciences of East China Normal University, and several senior scientists from academia and industry. The core members enjoy extensive expertise across key functional areas including gene editing, delivery system targeting multiple tissue types, and manufacturing process.

K2 Venture Partners invested in its Series Angel as the sole institutional investor in 2021 and was deeply involved in the company's establishment. It has continuously supported the company in subsequent rounds.

Exegenesis Bio is an innovative biotech company that provides accessible gene therapy for patients around the world. Exegenesis Bio was founded in Hangzhou, China in 2019. The company's AAV gene therapy EXG001-307 for SMA Type I, delivered via i.v., is the first one to have entered clinical trials in China. Based on innovative vectors such as AAV and lenti virus, the company has built a strong pipline of multiple programs, with fully integrated manufaturing capabiltiies, targeting diseases in liver, ophthamology and CNS. The founding team has extensive leadership experience at leading US and Global gene and cell therapy companies across all functional areas.

K2 Venture Partners led the angel round of financing in early 2019 and was deeply involved in the company's establishment, and continued to support it through subsequent rounds.

Founded in 2016, Phanes Therapeutics is a biotechnology company focusing on the research and development of drugs in immunoncology and ophthalmology, operated in Shanghai, China and San Diego, US. Based on its propriatary antibody technology platforms PACbody™, ATACCbody™ and SPECpair™, the company has built a strong pipline portfolio of first-in-class and best-in-class programs. Both the bispecific antibody programs PT217 and PT886 have been granted orphan drug designation by the US FDA.

Phanes Therapeutics was founded by Dr. Ming Wang, former VP of Johnson & Johnson. The founding team also includes a number of senior scientists who have worked at Pfizer, Amgen and other Big Pharma, with decades of experience in drug development.

K2 Venture Partners led its Series A financing in 2018.

GluBio Pharmaceutical is a new drug research and development company focusing on proteolysis targeting chimera (PROTAC). It was established in Shanghai, China and San Diego, USA in 2021. GluBio Pharmaceutical develops a new generation of molecular glue and PROTAC drugs for pathogenic targets that were previously considered "undruggable". The company has laid out multiple pipelines with first-in-class and best-in-class potential and built an innovative platform based on molecular glue and new target discovery technology. Multiple drugs for the treatment of hematological tumors and solid tumors have entered the preclinical research stage.

GluBio Pharmaceutical's founding team has rich experience and technical expertise in PROTAC and their professional background and practical experience cover all aspects of the development of such drugs.

K2 Venture Partners participated in its angel round financing in 2021.

CirCodeBio is an innovative biotechnology company focusing on the development of circular RNA nucleic acid drugs. It was established in Shanghai, China in 2018. CirCodeBio focuses on the development of therapeutic drugs and vaccines utilizing its unique global cRNA technology platform based on Group II intron self-catalysis. CirCodeBio has deeply explored the potential of cRNA and strives to become a leading cRNA company that benefits patients in China and the world.

CirCodeBio Bio was co-founded by Dr.Zefeng Wang, the director of the Key Laboratory of Computational Biology of the Chinese Academy of Sciences, leader of the RNA Systems Biology Research Group, and his postdoctoral collaborator Dr. Yang Yun. CirCodeBio Bio has accumulated experience in cRNA engineering based on the research results in decades.

K2 Venture Partners lead its Pre-A round of financing in 2021.

Founded in Suzhou, China in 2021, RinuaGene is a mRNA platform company. Based on its self-developed technology of mRNA design, chemical modification and LNP delivery, RinuaGene has developed a comprehensive platform that ahieves globally top levels of delivery efficiency, tissue specificity, and protein expression stability. The platform will be used to design and develop infectious diseases vaccines and therapies for cancer.

The founding team have decades of industry experience in innovative drug research and development covering early discovery, manufacturing and development.

K2 Venture Partners participated in the establishment of the company and led the Pre-A round of financing in 2021.

PrimeGene Therapeutics is an innovative specialty pharma company focusing on discovery, development and commercialization of innovative therapies, especially external medicines, for immune/inflammatory diseases in dermatology and ophathamology. PrimeGene Therapeutics was founded in Beijing, China in 2016. The founding team has decades of industry expertise in all functional areas from early discovery through commercialization.

K2 Venture Partners invested in PrimeGene Therapeutics in 2021 and continously supported in subsequent rounds.

Founded in Beijing in 2017, Sironax is a clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple first-in-class or globally leading programs, including both small molecule and biologics. The lead RIPK1 program is comprised of several chemically differentiated small molecule inhibitors, including SIR0365—which has completed two Phase 1b patient studies—in addition to SIR2446, which is now in a Phase 1a study in healthy volunteers.

Sironax was co-founded by Dr. Xiaodong Wang and Dr. Zhang Zhiyuan. Dr. Wang is a member of United States National Academy of Sciences and the Howard Hughes Medical Institute, a foreign academician of the Chinese Academy of Sciences and the director of the National Institute of Biological Sciences, Beijing. Dr. Zhang Zhiyuan is a senior researcher at the National Institute of Biological Sciences, Beijing. The leadership team have extensive experience of R&D and management in the biopharmacuetical industry.

K2 Venture Partners participated in its series A financing in 2018.

Founded in Shanghai in 2018, Tyligand is a clinical-stage biotech company that focuses on the discovery and development of small molecule therapeutics to help patients with drug-resistant cancer.

Relying on the in-depth understanding of biology and extensive experience in synthetic chemistry, Tyligand aims to develop highly selective small molecules to achieve multi-level, precise regulation of the signaling protein phosphorylation, and to offer safer, more effective and economical solutions to patients. The company has built a pipline with multiple Best or First -in- Class potential programs.

K2 Venture Partners participated in the Pre-A round of financing in 2018.

Founded in Suzhou, China in 2021, Neuro3 Therapeutics is a biotech company focusing on developing innovative therapeutics treating central nervous system diseases.

The company is committed to the development of technology platforms that can penetrate the blood-brain barrier as well as the development of small molecules. The founding team has extensive experience in all the functional areas of drug development for central nervous system diseases.

K2 Venture Partners led the Series Pre-A Financing in 2021 and was deeply involved in the company establishment.

Founded in 2022, CoJourney Bio is a CDMO specializing in cell and gene therapy. The company integrates the production, analysis, and detection of plasmids, viral vectors, and mRNA. CoJourney offers customized services, including process development, cGMP production, analytical method development, and product testing and release. CoJourney’s cGMP production facilities comply with FDA, EU, and NMPA regulations and are equipped with world-class R&D capabilities and state-of-the-art facilities. The founding team comprises senior CMC experts with commercial-scale gene therapy experience and outstanding scientists.

Headquartered in Zhejiang, China, and Philadelphia, USA, CoJourney operates globally.

K2 Venture Partners played a significant role in the company’s establishment and participated in its Series Angel Investment in 2023.

Cornerstone Robotics is a leading innovative surgical robot R&D company founded in Shenzhen, China and Hong Kong, China in 2019.

The first-generation porous laparoscopic surgical robot independently developed by Cornerstone Robotics has entered the clinical trial stage in 2022, and has completed the first batch of human clinical trials. Cornerstone Robotics actively leverages the advantages of its technology platform to simultaneously expand into other areas of specialized surgery.

The R&D team of Cornerstone Robotics is composed of the world's top surgical robot experts scientists in the industry, while the size of the plants for mass manufacturing is continuously growing, as is the high-level business team.

K2 Venture Partners participated in Cornerstone Robotics's A round of financing and continued to support subsequent rounds of financing.

Eyebright Medical (688050) is an innovative ophthalmic medical device company, mainly developing products in both surgery and optometry. The core products of Eyebright include intraocular lenses for surgery, orthokeratology lenses for optometry and a series of supporting products. Eyebright aims at developing a full range of ophthalmic medical products, such as implantable ophthalmic consumables, surgical instruments, surgical equipment, optometry products, ophthalmic preparations etc., covering cataracts, refractive errors, glaucoma, fundus lesions and other fields as an innovative leader in the domestic ophthalmic medical field.

K2 Venture Partners participated in the D round of financing in 2018.

Tendfo develops innovative interventional medical devices focusing on thrombus removal. Tendfo was founded in Shanghai in 2020.

Tendfo conducts the first clinical research on interventional thrombectomy stents for acute pulmonary embolism. The self-developed pulmonary artery thrombus removal system Tendvia™ is currently in the clinical trial stage. The second core product, a scavenging system of deep vein thrombosis , has entered clinical trials in 2022.

The founder of Tendfo has more than 10 years of R&D experience of endovascular interventional devices. The core team has also worked on multiple types of cardiovascular and cerebrovascular interventional medical devices.

K2 Venture Partners participated in Tendfo's Pre-A round and A round of financing.

Aureka Biotechnologies is a biotech committed to democratizing the pharmaceutical industry. The company develops a therapeutic discovery platform that uniquely integrates high-throughput, single-cell-based functional screening, synthetic biology-based autonomous discovery, and generative AI-based molecule design and multi-objective optimization. Empowered by large-scale, multi-metric data and reinforcement learning, Aureka’s AI solutions uncovers therapeutic design principles and exponentially accelerate the discovery of a wide range of macromolecule including bispecific antibodies, TCR-T, ADCs, peptides, as well as new therapeutics for previously challenging targets such as GPCRs. 

Spatomics, founded in 2023, is a life science tool innovation company with industrial leading expertise and exclusively licensed patents that focus on spatial omics. The company has developed the world’s first end-to-end ultrahigh-plex multi-omics platform with best-in-class sensitivity, compatibility, throughput, and cost. Spatomics is aiming to transfer the advanced spatial biology tools from research use only to widely accessible by translational and clinical applications.

K2 Venture Partners led the Angel round of financing in 2023 and was deeply involved in the company establishment.

Derism develops innovative blood glucose monitoring sensor CGM. Derism was established in Beijing in 2020.

Based on the self-developed platform of CGM material process technology, Derism has abundant technical accumulations in terms of the upgraded blood glucose electrode-sensing system, the efficient processing and the highly-stable semi-permeable membrane. The product of Derism can be exempted from in-plant calibration while ensuring the performance to be the same level as the world's leading competitors for 14 days. The founding team of the company has first-line CGM design and production experience in major overseas factories.

K2 Venture Partners has participated in Derism's Pre A and A rounds of financing.

SpearBio is an innovative developer of small-sample, ultrasensitive protein-detection technology that uses just a finger prick or dried blood samples to empower disease research, patient care, and drug development.

The founder, Professor Peng Yin, a world-renowned scientist of DNA nanotechnology, is from the Wyss Institute of Harvard University and has been published in multiple papers in Nature, Science, and Cell.

The DNA-nanotechnology driven SPEAR technology is superior to other protein detection assays in its combination of extreme sensitivity, wash-free workflow, high dynamic range, small volume, low cost and the fact that it can be read out using common quantitative PCR equipment. SpearBio is working towards commercializing the NAB-Sure™ SARS-CoV-2 test kit, which is the world’s first assay to accurately assesses levels of SARS-CoV-2-neutralizing antibodies in dried-blood spot samples.

K2 Venture Partners invested in SpearBio in 2022.

Agilis Robotics a leading developer of flexible robotic instruments designed to support endoscopic surgery, established in Hong Kong, China in 2021. Agilis Robotics also has branches in Shenzhen and Guangzhou.The self-developed flexible robot arm is the world's smallest known robot and the only product that are compatible with all kinds of endoscopes worldwide. Research and development progress is at the leading level in the world. Agilis Robotics has completed their first animal test at CUHK, successfully resecting artificial bladder tumors in a pig.

The core team of Agilis Robotics includes scientists from the Department of Mechanical Engineering of the University of Hong Kong, senior practitioners in industry and finance, with world-leading professional level and market control.

K2 Venture Partners participated in its A-round financing in 2022, deeply participated in the company's preparation process, and continued to support it in subsequent rounds.

Scisoon develops innovative diagnosis and treatment for clinical diseases utilizing molecular genetic testing and personalized health management services based on the self-developed genetic testing platform. Scisoon was founded in Beijing in 2015.

Scisoon is commited to the vision of Closer to the Clinic in terms of oncology in reproductive health and preventive health. In the field of reproductive health, Scisoon has developed Youxinan, the leading non-invasive prenatal genetic testing system based on the self-developed Bayesian statistical algorithm.In the field of tumor diagnosis and treatment, Scisoon has dual platforms of ctDNA and CTC liquid biopsy to facilitate early tumor screening as well as medication guidance, prognosis assessment and dynamic monitoring.

K2 Venture Partners participated in Scisoon's A round of financing in 2017.

Based on brain connectomics, Xijia Medical specializes in brain network analysis, therapy planning, and therapy services, along with providing supporting hardware and software. The company originated from the China division of Omniscient Neurotechnology, a global leader in brain-network connectivity. Omniscient is renowned for being the first and only organization to successfully commercialize connectomic brain-map products, with its FDA-approved Brain Connectomics Atlas software boasting one of the largest brain scan databases worldwide.

The founding team comprises top experts in neurosurgery and brain connectomics, alongside seasoned business management professionals.

In 2024, K2 Venture Partners was depply invovled in the company’s establishment and led Series Angel Financing round.

Founed in Nanjing, China in 2016, LanSionBio is a company that develops, produces and sells POCT diagnostic reagents and instruments. LanSionBio owns nearly 300 core intellectual property rights. The self-developed diagnostic products can meet the comprehensive needs of clinical departments including outpatient, emergency departments and cardiology departments for tertiary hospitals and small & medium-sized medical institutions. LanSionBio has exported products to nearly 100 countries and regions.

K2 Venture Partners participated in its A round of financing in 2018.

Richen Force Holdings is an innovative medical device company focusing on the research and development of digestive tract disease detection instruments, established in Beijing, China in 2002. In the field of breath test, Richen Force Holdings is the earliest player in China that has obtained SFDA approval as well as CE certification and has independent intellectual property rights that can simultaneously produce the equipment and reagents. The Carbon13 breath test diagnostic system developed by the company is the gold standard written into clinical guidelines for the detection of Helicobacter pylori because of its high sensitivity and specificity. Richen Force Holdings continuously launched new products such as capsule endoscopes and disposable endoscopes.

K2 Venture Partners participated in the company's B round of financing in 2016 and continues to support subsequent rounds of financing.